Condition: Breast Cancer · Sponsor: Imperial College London
This mechanistic study will be the first study to assess the efficacy of \[18F\]GE-226 to target HER2 expression in patients with metastatic breast cancer. The study will establish the pharmacokinetics of \[18F\]GE-226 and the optimum time-point for performing static scans in this patient population.
This description comes directly from the study's public registry record.
HERPET Trial Coordinator · 0207 59 42804 · herpet@imperial.ac.uk; g.gopalakrishnan@imperial.ac.uk
Gosala Gopalakrishnan, PhD · 0207 59 42804 · g.gopalakrishnan@imperial.ac.uk
Always discuss trial participation with your own doctor first.
| Imperial College Healthcare NHS Trust | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03827317